Surviving Mesothelioma a Patients Guide

Alabama Mesothelioma Fact Sheet

While mesothelioma is a problem in all states, the specific incident rate for Alabama is 0.8 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in AL, recent AL mesothelioma-related court cases, mesothelioma specialists in AL and potential asbestos hotspots in Alabama.

Alabama Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Alabama

Alabama Research and Clinical Trials
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Alabama Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Alabama Cases
This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
Henderson v. Meadwestvaco Corp.
1070522, 1070497, 1070509, SUPREME COURT OF ALABAMA, March 20, 2009, Released
GMC v. Kilgore
1002149 , SUPREME COURT OF ALABAMA, December 20, 2002, Released
Southern Bakeries, Inc. v. Knipp
1010743 , SUPREME COURT OF ALABAMA, December 13, 2002, Released
Greene v. Csx Transp.
1010357 , SUPREME COURT OF ALABAMA, August 30, 2002, Released
Ex parte Wilkerson
1990769, SUPREME COURT OF ALABAMA, September 8, 2000, Released
Wilkerson v. Burlington N. R.R.
2980962, COURT OF CIVIL APPEALS OF ALABAMA, September 24, 1999, Released
Hospitals and Cancer Centers

University of Alabama at Birmingham Comprehensive Cancer Center
1824 6th Ave. S. 236 TI
Birmingham, AL


Dr. Robert J. Cerfolio
Thoracic Surgeon
University of Alabama at Birmingham
Department of Cardiothoracic Surgery
703 19th Street
Birmingham, Alabama 35294
Athens Browns Ferry Nuclear Plant
Bessemer Bessemer Steel Mill
Decatur Amoco Chemical
Redstone Arsenal
Eden Dan River Power Station
Fort Rucker Fort Rucker Boiler Plant
Gorgas Alabama Power Plant
Homestead Turkey Point Powerhouse
Mobile Addsco Shipyard
Admiral Sims Motor Hotel
Alabama Dry Dock
Bender Shipyard
GAF Plant
Gulf Engineering
Gulf Shipyard
Mobile Shipyard
Ruberoid Plant
Montgomery GE Fiber Plant
Opelika Sewing Mil
WestPoint Teppermill Cotton Mill
Selma Dan River Cotton Mill
Theodore Great Plains Pipeline
Robert, Francisco Onconase Vs Doxorubicin In Malignant Mesothelioma
Grant: 5M01RR000032-390649
Abstract: Doxorubicin is a commonly used chemotherapy agent in the treatment of malignant mesothelioma. Onconase is an experimental (not approved by the FDA) drug that has shown activity against malignant mesothelioma. The purpose of this study is to determine whether Onconase, when administered into the blood stream, is better than injection of Doxorubicin into the blood stream for the treatment of malignant mesothelioma. Approximately 160 patients across the country will be enrolled on this study. These patients will receive either Onconase by intravenous infusion over 30 minutes weekly, or Doxorubicin every 3 weeks for a maximum of 6 doses. Treatment will continue for at least 18 weeks or until the tumor is no longer responding to treatment. After treatment has been stopped, patients will be monitored by a physician to determine late side effects and future therapy.

Tags: Antineoplastic, Doxorubicin, Human Therapy Evaluation, Mesothelioma, Neoplasm /cancer Chemotherapy Clinical Trial Clinical Research, Human Subject

  • Followup Grant: 5M01RR000032-400649
  • Followup Grant: 5M01RR000032-410649
  • Followup Grant: 5M01RR000032-420649
Clinical Trials
Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin;   Drug: gemcitabine hydrochloride
More Information
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: MORAb-009 by IV on Days 1 and 8 every 21 days for 6 cycles.
More Information
Condition: Lung Cancer;   Malignant Mesothelioma;   Pancreatic Cancer;   Sarcoma
Intervention: Drug: L-alanosine
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride;   Drug: gemcitabine hydrochloride
More Information

Mesothelioma Info